Adriamycin, BCNU, and cyclophosphamide in drug-resistant adenocarcinoma of the ovary.
Because of an encouraging response rate in a pilot study of adriamycin, BCNU, and cyclophosphamide (ABC), the Southeastern Cancer Study Group conducted a phase II study of ABC in patients with melphalan-resistant ovarian carcinoma. Of 36 evaluable patients, there were only 4 partial responses to therapy, for a partial response rate of 11%. Durations of response were 4 to 50 + weeks, and the overall median survival was 29 weeks. No complete responses were seen. Dose-limiting toxicity was granulocytopenia. We conclude that ABC is generally ineffective in management of alkylator-resistant ovarian adenocarcinoma.
D000230:Adenocarcinoma / Q000188:drug therapy*; D000380:Agranulocytosis / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols; D002330:Carmustine / Q000009:adverse effects / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000009:adverse effects / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000627:therapeutic use; D004341:Drug Evaluation; D004351:Drug Resistance; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D003520:Cyclophosphamide; D008558:Melphalan; D002330:Carmustine